Use of Immunosuppression and the Risk of Subsequent Overall or Cancer Mortality
John H. Kempen, Craig Newcomb, Terri Washington, C. Stephen Foster, Lucia Sobrin, Jennifer E. Thorne, Douglas A. Jabs, Eric B. Suhler, James T. Rosenbaum, H. Nida Sen, Grace A. Levy-Clarke, Robert B. Nussenblatt, Nirali Bhatt, Careen Y. Lowder, Debra A. Goldstein, Yannek I. Leiderman, Nisha R. Acharya, Gary N. Holland, Russell W. Read, James P. Dunn, Kurt Dreger, Pichaporn Artornsombudh, Hosne Ara Begum, Tonetta D. Fitzgerald, Srishti Kothari, Abhishek R. Payal, Ebenezer Daniel, Sapna Gangaputra, R. Oktay Kaçmaz, Teresa L. Liesegang, Siddharth S. Pujari, Naira Khachatryan, Armin Maghsoudlou, Hilkiah K. Suga, Clara M. Pak, Kathy J. Helzlsouer, Jeanine M. Buchanich
Topics & Concepts
MedicineInternal medicineAzathioprineHazard ratioImmunosuppressionCalcineurinPopulationStandardized mortality ratioEtanerceptCancerNational Death IndexRetrospective cohort studyInfliximabRisk of mortalitySurgeryConfidence intervalTransplantationDiseaseTumor necrosis factor alphaEnvironmental healthOcular Diseases and Behçet’s SyndromeOcular Oncology and TreatmentsIgG4-Related and Inflammatory Diseases